Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$0.14 - $0.21 $61 - $91
438 Added 89.02%
930 $0
Q3 2022

Nov 14, 2022

SELL
$0.14 - $1.83 $74,956 - $979,782
-535,400 Reduced 99.91%
492 $0
Q2 2022

Aug 12, 2022

BUY
$1.34 - $2.08 $69,022 - $107,138
51,509 Added 10.63%
535,892 $862,000
Q1 2022

May 16, 2022

BUY
$1.1 - $2.17 $531,839 - $1.05 Million
483,490 Added 54142.22%
484,383 $731,000
Q4 2021

Feb 08, 2022

SELL
$1.99 - $3.1 $192,090 - $299,236
-96,528 Reduced 99.08%
893 $2,000
Q3 2021

Nov 15, 2021

BUY
$2.47 - $3.34 $233,343 - $315,533
94,471 Added 3202.41%
97,421 $303,000
Q2 2021

Sep 13, 2021

BUY
$2.56 - $3.35 $7,552 - $9,882
2,950 New
2,950 $9,000

Others Institutions Holding OBSV

About ObsEva SA


  • Ticker OBSV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,499,200
  • Description
  • ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...
More about OBSV
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.